Skip to content
Independent · Sourced

Ontario Denied Dying Cancer Patient Out-of-Country Treatment — Court Quashed the Decision

TL;DR

Ontario refused to pay for Alex Shved, a Toronto father with stage 4 melanoma, to get a Health Canada-approved cell therapy in the U.S. On Sept 22, 2026, a three-judge Divisional Court panel quashed that refusal as unreasonable and ordered a new decision by Oct 2, noting he "will likely be dead by Christmas" without treatment.

Who was hurt

  • Alex Shved

    Ontario denied Shved out-of-country funding for tumour-infiltrating lymphocyte (TIL) therapy, a Health Canada-approved treatment for his stage 4 melanoma. He sought judicial review and represented himself at the September 8, 2026 hearing. On September 22, 2026, the Divisional Court quashed the denial as unreasonable and ordered a new decision by October 2, finding the record showed he "will likely be dead by Christmas if he does not receive the requested treatment within a few weeks" (Star, Globe).

Connections graph

Key: People Related scandals

Why it matters

Alex Shved is a 37-year-old Etobicoke father of two young daughters with metastatic (stage 4) melanoma. He wants tumour-infiltrating lymphocyte (TIL) therapy, sold as lifileucel (brand name Amtagvi). Health Canada approved it (in August 2025, according to the Globe and Mail), but provincial drug plans do not cover it yet. He applied to Ontario for out-of-country coverage and was refused. His appeal to the Health Services Appeal and Review Board was dismissed, the Toronto Star reported.

On Sept 22, 2026, a three-judge panel of the Divisional Court (Ontario Superior Court of Justice) set aside those decisions. It found the justifications unreasonable and inadequately explained. The court's reasons, quoted by both outlets, said: "The record discloses that he will likely be dead by Christmas if he does not receive the requested treatment within a few weeks." According to the Star, the panel also said the province "provided no evidence" that funding his treatment would undermine drug-price negotiations.

The province's position is on the record. The Globe reported that Ontario told Shved the out-of-country program "isn't intended to be used as an interim funding route" for drugs that could later get public coverage. Before the ruling, a spokesperson for Health Minister Sylvia Jones told the Star that provinces do not fund out-of-country treatment for drugs that have not finished Canada's drug-funding process. The Star notes that this process "can take more than two years." Jones's office did not comment on the ruling.

The outlets report the cost differently, and the two figures measure different things. The Star reports that a Florida hospital quoted $1.3 million in total. The Globe reports that one lifileucel treatment costs US$515,000, not counting the hospital stay.

Rippling effects

The ruling sent the matter back, rather than directing an outcome, to the executive officer of the Ontario Public Drug Programs. A new decision is due by Oct 2, 2026, the Star reported. The court expedited the review.

The panel was not unanimous on what should happen next. According to the Globe, Justices Jean-Marc Labrosse and Sharon Shore formed the majority. Justice David Corbett agreed that the decisions should be quashed, but he would have directed the executive officer to recommend the treatment.

Shved says his case is not the only one. He told the Star that he knows of at least two Ontario patients with the same cancer who died after being denied out-of-country TIL access. He also told the Globe that he spoke directly with Minister Jones and that "she has done nothing." These are Shved's own claims. Jones's office did not comment on the ruling.

The case turns on a gap in timing. A treatment can be approved by Health Canada but not yet covered by provincial drug plans, and the province's position is that the out-of-country program should not fill that gap while the national funding process runs, a process the Star says "can take more than two years." In Shved's case, the court found the province's justifications for refusing him unreasonable and inadequately explained, and it gave Ontario until Oct 2 to decide again.

The October 2026 rule change. On Oct. 6, 2026 the province amended Regulation 552 of the Health Insurance Act to narrow out-of-country drug funding. The Trillium reported that the change is retroactive to Oct. 1, 2011 and could affect applications and appeals already under way, and that the province said it would limit a rise in requests "which would otherwise incur up to $170 million in additional annual costs." The government also said the change would avoid "up to $5.2 billion" in additional costs every year. The Canadian Press reported that the source of that figure was unclear in the release, and that a government official later explained it as the additional cost if the province entirely stopped negotiating drug prices with manufacturers for public coverage. A second patient, Sabrina Apitz-Grossman, filed for judicial review of her own denial the same day (The Trillium).

Sources

  1. Ontario must reconsider denying cancer patient access to new treatment in U.S., court rules — Toronto Star
  2. Ontario court sides with patient appealing province's refusal to cover out-of-country cancer treatment — The Globe and Mail
  3. Ontario court orders 3rd OHIP review of out-of-country treatment for man with terminal cancer — CBC News
  4. Ontario Clarifies Longstanding Out-of-Country Drug Funding Process — Ontario Newsroom
  5. Toronto cancer patient feels 'betrayed' as Ontario tightens rules on out-of-country funding — Toronto Star
  6. 'People are just being told to die': Cancer patient takes Ford government to court for refusing to fund potentially life-saving U.S. treatment — The Trillium
  7. Ontario drug funding decision leaves cancer patients disappointed, with few options — CTV News (The Canadian Press)
  8. 'These are very challenging decisions': Health minister defends out-of-country drug funding rules as cancer patients face limited options — NWONewsWatch (The Trillium)
  9. Hansard, Legislative Assembly of Ontario, Oct. 27, 2026 (Question Period: Health care funding)
  10. Hansard, Legislative Assembly of Ontario, Oct. 28, 2026 (Question Period: Health care funding)
  11. Legislative Assembly of Ontario: Hansard, Nov. 4, 2026
  12. The Trillium: Ontario refused cancer patient's U.S. treatment and never told her its own health agency recommended funding it, FOI reveals
  13. CTV News Toronto: 'The clock is ticking:' Ontario woman says she was denied coverage for drug to treat her rare cancer
  14. Legislative Assembly of Ontario: Hansard, Nov. 5, 2026
↑↓ move↵ focus⌘↵ open page→ start a path from here